|
28 Sep 2022 |
Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis
|
|
28 Sep 2022 |
Ichnos Sciences announces initiation of first-in-human study for ISB 1442
|
|
28 Sep 2022 |
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
|
|
28 Sep 2022 |
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
|
|
28 Sep 2022 |
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
|
|
28 Sep 2022 |
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
|
|
28 Sep 2022 |
CinRx Pharma Announces First Study Participant Dosed in CinFina’s Phase I Multiple Ascending Dose (MAD) Study of CIN-109 for the Treatment of Obesity
|
|
28 Sep 2022 |
Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis
|
|
28 Sep 2022 |
Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody
|
|
28 Sep 2022 |
Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma® (bevacizumab-adcd) for the Treatment of Six Types of Cancer
|
|
28 Sep 2022 |
Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology
|
|
28 Sep 2022 |
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate
|
|
28 Sep 2022 |
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
|
|
28 Sep 2022 |
Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL
|
|
28 Sep 2022 |
Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
|
|
28 Sep 2022 |
Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib
|
|
28 Sep 2022 |
Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors
|
|
28 Sep 2022 |
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
|
|
28 Sep 2022 |
Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
|
|
28 Sep 2022 |
Lecanemab confirmatory phase 3 Clarity AD study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer's disease
|
